DEX IR tablets — Competitive Intelligence Brief

DEX IR tablets (DEX IR tablets) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Central nervous system stimulant. Area: Attention deficit hyperactivity disorder (ADHD), Narcolepsy.

phase 2 Central nervous system stimulant Attention deficit hyperactivity disorder (ADHD), Narcolepsy Small molecule

Target snapshot

DEX IR tablets (DEX IR tablets) — Prof. Dr. Frank Behrens. DEX IR tablets are a type of dextroamphetamine, a central nervous system stimulant that works by increasing the levels of certain neurotransmitters in the brain.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
DEX IR tablets TARGET	DEX IR tablets	Prof. Dr. Frank Behrens	phase 2	Central nervous system stimulant
Vyvanse	LISDEXAMFETAMINE	Takeda	marketed	Central Nervous System Stimulant	Sodium-dependent dopamine transporter	2007-01-01
Focalin	DEXMETHYLPHENIDATE	Novartis	marketed	Central Nervous System Stimulant	Sodium-dependent dopamine transporter	2001-01-01
DIHYDROCODEINE BITARTRATE	DIHYDROCODEINE BITARTRATE		marketed	Central Nervous System Stimulant [EPC]		1983-01-01
Pyrilamine	mepyramine	Impax Labs	marketed	Central Nervous System Stimulant [EPC]	Histamine H1 receptor	1973-01-01
PYRILAMINE	PYRILAMINE		marketed	Central Nervous System Stimulant [EPC]		1973-01-01
PYRILAMINE MALEATE	PYRILAMINE MALEATE		marketed	Central Nervous System Stimulant [EPC]		1973-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Central nervous system stimulant class)

1. Impax Laboratories, LLC · 2 drugs in this class
2. Janssen-Cilag International NV · 2 drugs in this class
3. Alza Corporation, DE, USA · 1 drug in this class
4. Assistance Publique Hopitaux De Marseille · 1 drug in this class
5. Eli Lilly and Company · 1 drug in this class
6. McMaster University · 1 drug in this class
7. McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. · 1 drug in this class
8. Nanogen Pharmaceutical Biotechnology Joint Stock Company · 1 drug in this class
9. Novartis · 1 drug in this class
10. Phytopharm Consulting Brazil · 1 drug in this class